31.07.2013 • News • BASF • Dede Willams • H1 results

BASF Aims to Top 2013 Figures Despite Weaker H1

The world's largest chemical producer found the going tougher than expected in the first half of 2013. Sales revenue increased by 4% to €8.1 billion, and EBIT before special items by 2.5% to €4 billion, In Q2, sales added 3% year-on-year to just under €18.4 billion, thanks to higher volumes and a strong performance of the Agriculture and Oil & Gas segments. However, EBIT before special items declined 5% to €1.8 billion. Meeting the earnings forecast announced at the beginning of 2013 now appears "significantly more challenging," BASF CEO Kurt Bock said, but stressed that the group still aims to top the 2012 figures. 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.